News & Updates

Treatment with larsucosterol is safe and well tolerated in patients with alcohol-associated hepatitis (AH), as shown in a recent study.

A 52-week course of intensified androgen-deprivation therapy (ADT) appears to extend prostate-specific antigen progression-free survival (PSA-PFS) in patients with biochemically recurrent prostate cancer (BRPC) compared with ADT alone, without prolonging time to testosterone recovery, according to the phase III open-label PRESTO trial.

Therapeutic drug monitoring (TDM) helps identify children treated by thiopurine for acute lymphoblastic leukaemia (ALL) and inflammatory bowel disease (IBD) who have not reached their target levels or are over treated, reports a recent study.